Trevena (TRVN) Reaches $1.91 Yearly Low; First Personal Financial Services Lifted Its Johnson & Johnson (JNJ) Stake

October 12, 2017 - By Vivian Currie

The stock of Trevena Inc (NASDAQ:TRVN) hit a new 52-week low and has $1.81 target or 5.00% below today’s $1.91 share price. The 9 months bearish chart indicates high risk for the $114.02M company. The 1-year low was reported on Oct, 12 by Barchart.com. If the $1.81 price target is reached, the company will be worth $5.70M less. About 1.54 million shares traded or 198.21% up from the average. Trevena Inc (NASDAQ:TRVN) has declined 52.53% since October 12, 2016 and is downtrending. It has underperformed by 69.23% the S&P500.

First Personal Financial Services increased Johnson & Johnson (JNJ) stake by 23.5% reported in 2017Q2 SEC filing. First Personal Financial Services acquired 2,552 shares as Johnson & Johnson (JNJ)’s stock rose 6.85%. The First Personal Financial Services holds 13,413 shares with $1.77M value, up from 10,861 last quarter. Johnson & Johnson now has $369.77B valuation. The stock rose 0.37% or $0.51 reaching $137.16 per share. About 879,327 shares traded. Johnson & Johnson (NYSE:JNJ) has risen 12.54% since October 12, 2016 and is uptrending. It has underperformed by 4.16% the S&P500.

Among 23 analysts covering Johnson & Johnson (NYSE:JNJ), 12 have Buy rating, 5 Sell and 6 Hold. Therefore 52% are positive. Johnson & Johnson had 72 analyst reports since August 7, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Monday, September 25 by Citigroup. On Monday, October 9 the stock rating was upgraded by Wells Fargo to “Buy”. The rating was maintained by Argus Research on Wednesday, April 20 with “Buy”. The firm earned “Buy” rating on Tuesday, July 18 by BMO Capital Markets. Barclays Capital maintained it with “Overweight” rating and $120 target in Wednesday, April 20 report. RBC Capital Markets maintained the stock with “Buy” rating in Friday, September 22 report. The firm earned “Buy” rating on Sunday, August 27 by RBC Capital Markets. The stock has “Buy” rating by BMO Capital Markets on Thursday, August 31. The rating was maintained by Piper Jaffray with “Hold” on Tuesday, July 18. The rating was upgraded by Goldman Sachs on Monday, March 14 to “Neutral”.

Investors sentiment decreased to 0.83 in 2017 Q2. Its down 0.03, from 0.86 in 2017Q1. It dived, as 50 investors sold JNJ shares while 878 reduced holdings. 105 funds opened positions while 667 raised stakes. 1.73 billion shares or 0.03% less from 1.73 billion shares in 2017Q1 were reported. Crestwood Gru Ltd Llc reported 211,673 shares stake. Corda Investment Mgmt Ltd Company accumulated 209,754 shares. Vista Cap Prtnrs reported 2,071 shares. Deprince Race And Zollo has 224,672 shares. Ronna Sue Cohen invested 3.48% in Johnson & Johnson (NYSE:JNJ). Deltec Asset Mgmt Limited Com holds 0.09% or 3,425 shares in its portfolio. Parametrica Management Ltd reported 0.32% of its portfolio in Johnson & Johnson (NYSE:JNJ). Los Angeles Cap Equity Inc holds 0.85% in Johnson & Johnson (NYSE:JNJ) or 1.03M shares. Ruggie Capital Gru invested 0.15% in Johnson & Johnson (NYSE:JNJ). Guardian holds 0.21% or 87,000 shares in its portfolio. Geode Capital Mgmt Ltd Liability Corp has invested 1.51% of its portfolio in Johnson & Johnson (NYSE:JNJ). Wealth Architects Limited Co reported 0.29% in Johnson & Johnson (NYSE:JNJ). Confluence Mgmt Limited Liability Co stated it has 1.01 million shares or 2.71% of all its holdings. Hengehold Cap Mgmt Limited Company has invested 0.67% in Johnson & Johnson (NYSE:JNJ). Sigma Planning Corporation has invested 0.97% in Johnson & Johnson (NYSE:JNJ).

Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The company has market cap of $114.02 million. The Firm is developing OLINVO, a u-receptor G protein pathway selective modulator for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It currently has negative earnings. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com